Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week
[ad_1] A sign of Swiss pharmaceutical giant Novartis is seen on the top of a building at Novartis Campus in Basel, northern Switzerland, on Sept. 9, 2025. Fabrice Coffrini | AFP | Getty Images Novartis is planning to buy U.S.-based biotech Excellergy for up to $2 billion, betting on a next-generation allergy treatment that may […]